| Prev Close | 78.56 |
| Open | 78.56 |
| Day Low/High | 78.56 / 80.08 |
| 52 Wk Low/High | 62.55 / 97.86 |
| Volume | 9.42M |
| Avg Volume | 12.27M |
AbbVie Inc. (ABBV)
80.10
1.50
2.00
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 1.48B |
| Market Cap | 111.33B |
| EPS | 5.30 |
| P/E Ratio | 40.32 |
| Div & Yield | 4.72 (5.80%) |
Gilead Leads a Biotech Rally
The sector saw solid performance this week as the biotech juggernaut mounted a long-overdue rally.
2 Safe and Cheap Health Care Stocks
These two will continue to churn out earnings growth.
AbbVie and Michael Kors Rally Amid a Mixed Market
The market has strengthened some since my last update. Apple (AAPL) definitely seems to acting better since its earnings report, and is back above some important moving-day averages. Jim Cramer is right about the stock -- it's one you should hold, n...
3 Health Care Names With Healthy Outlooks
AbbVie, Teva and Zimmer Biomet posted solid quarters and are upbeat about the road ahead.
Hewlett Packard Split Gets Analysts' Attention; Abbvie Gets Upgraded
In Monday's analysts' actions, one Wall Street firm is weighing in on the Hewlett Packard split and another firm is giving Abbvie (ABBV) a rating and target price boost.
Closing Bell: AbbVie Climbs on Sales Jump; Stocks Up in October
Stocks ended slightly lower Friday, but enjoyed their best monthly gain in four years in October.
It's One Yawner of a Trading Day
Markets are now up slightly in what is one of most listless trading sessions to end a month that I recall lately. Not much moving. As previously noted, AbbVie (ABBV) might be the standout in the S&P 500 today. It's up more than 10% in trading today...
3 Stocks to Watch Today
Futures are up as we get less than an hour from the opening bell for October's last trading day. Earnings reports continued to hit fast and furious this morning, as about one third of S&P 500 companies report quarterly numbers this week. Here are th...
What to Watch Friday: AB InBev Hands Us Its Latest Earnings on Tap
For Friday October 30, TheStreet awaits quarterly results from Exxon Mobil (XOM), Chevron (CVX), Phillips 66 (PSX), Anheuser-Busch InBev (BUD), CVS Health (CVS) and AbbVie (ABBV).
Here's What I See in Apple and Amazon
The Apple breakout over $117 now measures to $127.
Gilead Wins in Hepatitis C Market
ABBV gets FDA warning on Viekira Pak drug, GILD reaps the reward.
Gilead Wins in Hepatitis C Market
ABBV gets FDA warning on Viekira Pak drug, GILD reaps the reward.
Biowreck (Part Deux)
The Food and Drug Administration warns of serious liver injury risk with AbbVie's (ABBV) hepatitis C treatments, Viekira Pak and Technivie. The stock is down by more than 12% on the news.
Biotechs, Autos Look Good in This Selloff
Put cash to work in large-caps that have become cheap in the current market.
Why I'm Adding to My Biotech Positions
I'll continue to add to Amgen, Teva and AbbVie incrementally as recent selloffs seem unwarranted.
My Take on Stock Buybacks
One of my favorite topics over the last few quarters has been stock-buyback programs. Companies like Apple (AAPL) have floated cheap debt to fund buyback programs and other things. I get it -- it's far cheaper to offer debt than perhaps deal with re...
AbbVie Looks Like It's Bottoming Out
Charts show the drug firm has a good entry point approaching.
Anchor Your Portfolio With a Sturdy Front 5
Just as the offensive line is vital to a team's success, so are consistent performers in a portfolio.
AbbVie Has More Downside to Go
The stock has shown awful relative strength.
Another Rally Fades Into the Sunset
China, and Fed rate hike uncertainty, continue to drive volatility.
Let's Go Bottom-Fishing!
The next couple of sessions offer an opportunity to nibble at four names with lower entry points.
Be Ready If This Is Just a One-Day Rally
Have your shopping list of stocks handy in case markets tank again.
Keep Calm and Shop for Bargains
It could be time to deploy some of your dry powder.
Shire Proposes $30B Deal to Buy Disease Specialist Baxalta
Shire (SHPG) has announced an offer to buy Baxalta (BXLT), a rare disease treatment specialist based in the U.S., for around $30.6 billion in stock.
Price Isn't a Problem for Gilead Sciences
Drugmaker has one of the best showings of earnings season.
Price Isn't a Problem for Gilead Sciences
Drugmaker has one of the best showings of earnings season.
Avoid Gilead Shares for Now
Competition and lower earnings cloud its future.
